The ureteral access sheath market is driven by the rising prevalence of urological disorders, such as kidney stones and ureteral strictures, which necessitate endoscopic procedures. Ureteral access ...

Trial-in-progress poster presentations will highlight the HERTHENA-PanTumor01 phase 2 trial evaluating patritumab deruxtecan in patients with a broad range of solid tumors including bladder ...

Two proffered paper sessions will highlight results from the ICARUS-BREAST01 phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR positive, HER2 negative advanced breast cancer ...

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

This mega deal, signed in October 2023 between Daiichi Sankyo and Merck & Co, was for the co-development and co-commercialization of Daiichi’s antibody‒drug conjugates (ADCs) patritumab ...

(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab) as ...

Shares of US protein-based vaccine developer Novavax (Nasdaq: NVAX) closed up 8.6% and added a further 1.8% to $12.60 in after-hours trading on Friday, on a positive development for its COVID-19 ...

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the ...